These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26124093)

  • 41. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
    Choi JH; Woo HM; Lee TY; Lee SY; Shim SM; Park WJ; Yang JS; Kim JA; Yun MR; Kim DW; Kim SS; Zhang Y; Shi W; Wang L; Graham BS; Mascola JR; Wang N; McLellan JS; Lee JY; Lee H
    PLoS One; 2020; 15(5):e0232757. PubMed ID: 32384116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MERS Vaccine Candidate Offers Promise, but Questions Remain.
    Menachery VD
    EBioMedicine; 2015 Oct; 2(10):1292-3. PubMed ID: 26629514
    [No Abstract]   [Full Text] [Related]  

  • 43. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
    Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
    Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex.
    Park BK; Maharjan S; Lee SI; Kim J; Bae JY; Park MS; Kwon HJ
    BMB Rep; 2019 Jun; 52(6):397-402. PubMed ID: 30355437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice.
    Niu P; Zhao G; Deng Y; Sun S; Wang W; Zhou Y; Tan W
    Sci China Life Sci; 2018 Oct; 61(10):1280-1282. PubMed ID: 30091015
    [No Abstract]   [Full Text] [Related]  

  • 47. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV.
    Fan C; Wu X; Liu Q; Li Q; Liu S; Lu J; Yang Y; Cao Y; Huang W; Liang C; Ying T; Jiang S; Wang Y
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30142928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.
    Du L; Tai W; Yang Y; Zhao G; Zhu Q; Sun S; Liu C; Tao X; Tseng CK; Perlman S; Jiang S; Zhou Y; Li F
    Nat Commun; 2016 Nov; 7():13473. PubMed ID: 27874853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein.
    Haverkamp AK; Bosch BJ; Spitzbarth I; Lehmbecker A; Te N; Bensaid A; Segalés J; Baumgärtner W
    Vet Immunol Immunopathol; 2019 Dec; 218():109939. PubMed ID: 31526954
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.
    Luke T; Wu H; Zhao J; Channappanavar R; Coleman CM; Jiao JA; Matsushita H; Liu Y; Postnikova EN; Ork BL; Glenn G; Flyer D; Defang G; Raviprakash K; Kochel T; Wang J; Nie W; Smith G; Hensley LE; Olinger GG; Kuhn JH; Holbrook MR; Johnson RF; Perlman S; Sullivan E; Frieman MB
    Sci Transl Med; 2016 Feb; 8(326):326ra21. PubMed ID: 26888429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.
    Houser KV; Broadbent AJ; Gretebeck L; Vogel L; Lamirande EW; Sutton T; Bock KW; Minai M; Orandle M; Moore IN; Subbarao K
    PLoS Pathog; 2017 Aug; 13(8):e1006565. PubMed ID: 28817732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bioinformatics-based Design of Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and Immunity analysis in Mice].
    Lan J; Lu S; Deng Y; Wen B; Chen H; Wang W; Tan W
    Bing Du Xue Bao; 2016 Jan; 32(1):77-81. PubMed ID: 27295887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
    Yang Y; Deng Y; Wen B; Wang H; Meng X; Lan J; Gao GF; Tan W
    Viral Immunol; 2014 Dec; 27(10):543-50. PubMed ID: 25387086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.
    de Wit E; Feldmann F; Horne E; Okumura A; Cameroni E; Haddock E; Saturday G; Scott D; Gopal R; Zambon M; Corti D; Feldmann H
    Antiviral Res; 2019 Mar; 163():70-74. PubMed ID: 30684561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
    Almasaud A; Alharbi NK; Hashem AM
    Methods Mol Biol; 2020; 2099():117-126. PubMed ID: 31883092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccines for the prevention against the threat of MERS-CoV.
    Du L; Tai W; Zhou Y; Jiang S
    Expert Rev Vaccines; 2016 Sep; 15(9):1123-34. PubMed ID: 26985862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
    Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection.
    Park SW; Perera RA; Choe PG; Lau EH; Choi SJ; Chun JY; Oh HS; Song KH; Bang JH; Kim ES; Kim HB; Park WB; Kim NJ; Poon LL; Peiris M; Oh MD
    Euro Surveill; 2015; 20(41):. PubMed ID: 26538277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea.
    Park WB; Perera RA; Choe PG; Lau EH; Choi SJ; Chun JY; Oh HS; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Man Poon LL; Peiris M; Oh MD
    Emerg Infect Dis; 2015 Dec; 21(12):2186-9. PubMed ID: 26583829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.
    de Wit E; Feldmann F; Okumura A; Horne E; Haddock E; Saturday G; Scott D; Erlandson KJ; Stahl N; Lipsich L; Kyratsous CA; Feldmann H
    Antiviral Res; 2018 Aug; 156():64-71. PubMed ID: 29885377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.